NCT07183189 2025-12-18
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
Clinical Trials
10 trialsNCT06417008 2025-08-01
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 2/3 Recruiting
NCT06951464 2025-07-23
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Sichuan University
Phase 2 Recruiting
NCT06604689 2024-11-12
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
Fudan University
Recruiting
NCT06300424 2024-04-17
NEOVADE
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT04401059 2023-12-27
SELECT-2
Hangzhou Normal University
Phase 4 Recruiting
NCT06102928 2023-10-26
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Kunming Medical University
Phase NA Recruiting
NCT06043973 2023-09-21
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Qianfoshan Hospital
Phase 3 Recruiting
NCT05800223 2023-04-05
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Shanghai Cancer Hospital, China
Phase 3 Recruiting
NCT04951635 2022-06-16
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Recruiting